Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06132256
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2023-11-09
Brief Title:
MAXPIRe Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis IPF
Sponsor:
Syndax Pharmaceuticals
Organization:
Syndax Pharmaceuticals
Study Overview
Official Title:
A 26-Week Randomized Double-Blind Placebo-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis IPF
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the efficacy and safety of axatilimab in participants with IPF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-502954-15-00 | OTHER | EU-CT | None |